# 🚀 Six Weeks to Finish Strong—and Build the Bridge to Sen‑Jam’s Future | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/362277
- Entity ID: wefunder:feed_item:362277
- Published at: 2026-08-02 21:47:19 UTC
- Updated at: 2026-08-03 03:10:47 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen‑Jam Investors & Community,We are entering the final six weeks of our current Wefunder offering—and we are doing it with momentum. 🚀Together, we have raised more than $265,000 in this round. This week, Wefunder expects to recognize Sen‑Jam in its weekly newsletter among the companies raising the most capital on the platform. 🏆That recognition is meaningful—but it is only the beginning.🌎 The Dream We Are BuildingAt Sen‑Jam, we believe resolving inflammation can empower people to live longer, healthier, and more resilient lives.We are building more than a pipeline of therapeutics. We are building a platform designed to:⚡ Accelerate therapeutic discovery💰 Reduce development costs🏃 Increase speed to patients🌍 Make life-changing medicines more accessible around the worldOur work is bigger than any one program, any one company, or any one of us.If we execute properly, everyone wins: patients, physicians, partners, investors, and humanity.🌉 Why These Six Weeks MatterOur original objective for this offering was to raise at least $3 million.Reaching that objective would provide Sen‑Jam with important operating runway and help position us to pursue a significantly larger institutional financing later this year.That future financing is intended to help us:🧬 Advance our clinical programs🤖 Expand Galaxy and Atlas🤝 Strengthen our strategic partnerships📈 Build toward the next stage of Sen‑Jam’s growthThe capital raised during these next six weeks can help us build the bridge from where we are today to where we believe Sen‑Jam can go.🎁 Our Six-Week Early-Action IncentiveTo reward investors who act earlier—and those prepared to make a larger commitment—we are introducing a limited, six-week step-down common-stock bonus.The minimum investment in the current convertible-note offering is $1,000. Common-stock bonuses begin with investments of $5,000, with higher bonus percentages available for larger commitments.⏳ Each incentive week ends Sunday night at 11:59 p.m. New York time. The $5,000 bonus decreases by one percentage point each week, while bonuses for investments of $10,000 or more decrease by 2.5 percentage points each week.This gives investors two ways to increase their potential common-stock bonus: Participate earlier—before the weekly percentage steps down. Make a larger commitment—qualifying for a higher investment tier. The underlying investment (Standard Terms) remains a convertible note with a $150 million valuation cap, 20% conversion discount, and 8% interest. The common-stock incentive would be issued separately, subject to final offering terms, eligibility requirements, corporate approvals, and applicable documentation.🤝 An Invitation to Build This With UsSen‑Jam currently has approximately 540 accredited investors on Wefunder and another 360 accredited investors following our progress.If you have been watching from the sidelines, this is our invitation to step into the Sen‑Jam dream.If you have already invested, this is an opportunity to deepen your participation at a moment when additional capital can have an outsized impact.And if you believe—as we do—that resolving inflammation could change how humanity approaches health, resilience, and longevity, we invite you to help us finish this campaign strong.We are not simply raising capital.We are creating the runway to pursue something much larger: a future in which more people can live longer, healthier, and more resilient lives. ❤️Let’s lift while we climb—and build a future where everyone wins. 🌎With gratitude,Jim👉 [Review the offering and participate through Wefunder]This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. Any offering is made solely through the applicable offering materials and is subject to eligibility requirements, risk factors, terms, conditions, and applicable securities laws. Investments in private companies are speculative, illiquid, and involve a substantial risk of loss.